Integrating Rapid Diabetes Screening Into a Latinx Focused Community-Based Low-Barrier COVID-19 Testing Program.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
02 05 2022
02 05 2022
Historique:
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
31
5
2022
Statut:
epublish
Résumé
Community-based COVID-19 testing and vaccination programs play a crucial role in mitigating racial and ethnic disparities in COVID-19 service delivery. They also represent a platform that can be leveraged to expand access to testing for chronic diseases, including diabetes, that disproportionately affect the Latinx community and other marginalized communities. To evaluate outcomes associated with a diabetes testing strategy designed to reach low-income Latinx persons by leveraging COVID-19 testing infrastructure and community trust developed during the COVID-19 pandemic. This health care improvement study was conducted from August 1 to October 5, 2021, at an outdoor, community-based COVID-19 testing site at a transport hub in the Mission Neighborhood in San Francisco, California. Because the program was designed to expand access to diabetes screening to the local community, all individuals presenting for on-site testing were eligible. Data were analyzed in November 2021. Integration of rapid, point-of-care hemoglobin A1c screening as a testing option in an existing low-barrier COVID-19 testing program. Evaluation was guided by the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework and utilized programmatic data and structured surveys among clients and staff. Of 6631 individuals tested (median [IQR] age 39.3 [29.7-51.3] years; 3417 [52.3%] female, 4348 [65.6%] Latinx), 923 (13.9%) underwent hemoglobin A1c testing with or without COVID-19 testing and 5708 (86.1%) underwent COVID-19 testing only. Individuals tested for diabetes were more likely to be Latinx (763 of 923 individuals [82.7%] who underwent testing were Latinx vs 3585 of 5708 [62.8%] not undergoing testing), have an annual household income of less than $50 000 (450 individuals [81.2%] vs 2409 individuals [66.0%]), and not have health insurance (381 individuals [47.2%] vs 1858 individuals [39.9%]), and 206 (48.0%) had never tested for diabetes before. Overall, 313 (33.9%) and 113 (12.2%) individuals had prediabetes and diabetes, respectively; only 141 of 354 of these individuals (39.8%) had a primary care clinician whom they had seen in the prior 12 months, which was lower among Latinx individuals (113 of 307 individuals [36.8%] vs 28 of 47 [59.6%]). Acceptability of the rapid testing program was high-98% were satisfied with their visit and 96% said they would return for future services; key factors underpinning acceptability included friendly staff, efficiency, and a convenient location. In this health care improvement study conducted within an existing community-based COVID-19 testing program, integrating rapid testing for diabetes was feasible, reached low-income Latinx individuals, and identified many persons with prediabetes and diabetes, most of whom lacked access to services in formal health care settings. Leveraging pandemic-related public health responses represents an important opportunity for engaging socioeconomically disadvantaged populations into care for diabetes.
Identifiants
pubmed: 35616939
pii: 2792722
doi: 10.1001/jamanetworkopen.2022.14163
pmc: PMC9136625
doi:
Substances chimiques
Glycated Hemoglobin A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2214163Références
J Diabetes Res. 2016;2016:2456518
pubmed: 26881242
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
Health Promot Pract. 2006 Jan;7(1):26-33
pubmed: 16410418
Open Forum Infect Dis. 2021 Jan 20;8(2):ofab023
pubmed: 33623805
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Am J Kidney Dis. 2019 Jan;73(1):102-111
pubmed: 29661541
Front Public Health. 2019 Aug 21;7:215
pubmed: 31497586
PLoS One. 2020 Oct 9;15(10):e0239400
pubmed: 33035216
J Ambul Care Manage. 2010 Apr-Jun;33(2):155-62
pubmed: 20228639
Lancet Glob Health. 2021 Jun;9(6):e749-e750
pubmed: 33713634
Int J Pharm Pract. 2013 Dec;21(6):349-61
pubmed: 23683090
Diabetes Res Clin Pract. 2016 Oct;120:73-80
pubmed: 27522562
Am J Prev Med. 2004 May;26(4):271-5
pubmed: 15110052
Prev Chronic Dis. 2020 Jul 16;17:E65
pubmed: 32678059
Prev Chronic Dis. 2021 Oct 07;18:E91
pubmed: 34618667
Diabetes Care. 2003 Mar;26(3):668-70
pubmed: 12610019
JAMA Intern Med. 2020 Apr 1;180(4):596-597
pubmed: 31985740
Annu Rev Public Health. 2016;37:375-94
pubmed: 26789384
Can Pharm J (Ott). 2012 Jul;145(4):165-7
pubmed: 23509544
Health Info Libr J. 2014 Dec;31(4):254-73
pubmed: 25209260
J Immigr Minor Health. 2014 Aug;16(4):565-75
pubmed: 24363118
J Am Pharm Assoc (2003). 2006 May-Jun;46(3):370-7
pubmed: 16739759
Front Public Health. 2017 Jun 12;5:135
pubmed: 28660184
Ethn Dis. 2014 Spring;24(2):195-9
pubmed: 24804366
JAMA. 2021 Feb 23;325(8):719-720
pubmed: 33480972
Am J Public Health. 2021 Apr;111(4):658-662
pubmed: 33600248
J Racial Ethn Health Disparities. 2021 Oct 13;:
pubmed: 34647273
Prev Chronic Dis. 2020 Dec 10;17:E158
pubmed: 33301390
Health Serv Res Manag Epidemiol. 2018 Jan 21;5:2333392817752211
pubmed: 29383325
PLoS One. 2021 Sep 20;16(9):e0257111
pubmed: 34543291
J Natl Med Assoc. 2004 Oct;96(10):1325-31
pubmed: 15540883
Am J Ophthalmol. 2010 May;149(5):752-61.e1-3
pubmed: 20149342
Am J Med. 2011 Oct;124(10 Suppl):S2-9
pubmed: 21939795
PLoS One. 2020 Jun 5;15(6):e0233839
pubmed: 32502193
Front Public Health. 2020 May 12;8:134
pubmed: 32478025